nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Biomarkers for Alzheimer’s disease trials — biomarkers for what? A discussion paper
|
Lovestone, S. |
|
2009 |
13 |
4 |
p. 334-336 |
artikel |
2 |
Biomarkers in clinical trials of Alzheimer Disease (AD): What is expected from regulatory agencies?
|
Sampaio, C. |
|
2009 |
13 |
4 |
p. 339-340 |
artikel |
3 |
Challenges in the conduct of disease-modifying trials in ad: Practical experience from a phase 2 trial of TAU-aggregation inhibitor therapy
|
Wischik, C. |
|
2009 |
13 |
4 |
p. 367-369 |
artikel |
4 |
Defining frailty — the holy grail of geriatric medicine
|
Conroy, S. |
|
2009 |
13 |
4 |
p. 389 |
artikel |
5 |
Enrichment of MCI and early Alzheimer’s disease treatment trials using neurochemical & imaging candidate biomarkers
|
Hampel, H. |
|
2009 |
13 |
4 |
p. 373-375 |
artikel |
6 |
Frailty: Defining and measuring of a concept
|
Pel-Littel, R. E. |
|
2009 |
13 |
4 |
p. 390-394 |
artikel |
7 |
Gerontology and geriatrics, a worldwide expansion in 2009: Data from the IAGG World Meeting Paris 2009, July 5–9th
|
Vellas, B. |
|
2009 |
13 |
4 |
p. 292 |
artikel |
8 |
How can we recognize “disease modification” effects?
|
Siemers, E. R. |
|
2009 |
13 |
4 |
p. 341-343 |
artikel |
9 |
Imaging and biomarkers will be used for detection and monitoring progression of early Alzheimer’s disease
|
Weiner, M. W. |
|
2009 |
13 |
4 |
p. 332-333 |
artikel |
10 |
Impact of food aid on food variety and dietary diversity of an elderly community in Sharpeville, South Africa
|
Oldewage-Theron, W. H. |
|
2009 |
13 |
4 |
p. 300-308 |
artikel |
11 |
Interest of the new criteria for drug trials in AD
|
Dubois, B. |
|
2009 |
13 |
4 |
p. 356-357 |
artikel |
12 |
Interpreting biomarker data in therapeutic trials
|
Aisen, P. S. |
|
2009 |
13 |
4 |
p. 337-338 |
artikel |
13 |
Knowing the natural course of biomarkers in AD: Longitudinal MRI, CSF and PET data
|
Flier, W. M. Van Der |
|
2009 |
13 |
4 |
p. 353-355 |
artikel |
14 |
Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer’s disease: The Alzhemedtm (Tramiprosate) experience
|
Saumier, D. |
|
2009 |
13 |
4 |
p. 370-372 |
artikel |
15 |
Metabolic response to a ketogenic breakfast in the healthy elderly
|
Freemantle, E. |
|
2009 |
13 |
4 |
p. 293-298 |
artikel |
16 |
Molecular imaging markers in clinical trials in Alzheimer’s disease
|
Nordberg, A. |
|
2009 |
13 |
4 |
p. 346-347 |
artikel |
17 |
Neuro-imaging: Structural and functional imaging
|
Frisoni, G. B. |
|
2009 |
13 |
4 |
p. 348-349 |
artikel |
18 |
Sleep disorders and their impacts on healthy, dependent, and frail older adults
|
Cochen, Valérie |
|
2009 |
13 |
4 |
p. 322-329 |
artikel |
19 |
Structural imaging markers for therapeutic trials in Alzheimer’s disease
|
Fox, N. C. |
|
2009 |
13 |
4 |
p. 350-352 |
artikel |
20 |
The association of thyroid stimulating hormone levels with cognitive function and depressed mood: The Rancho Bernardo study
|
Kritz-Silverstein, D. |
|
2009 |
13 |
4 |
p. 317-321 |
artikel |
21 |
The validity of biomarkers as surrogate endpoints in Alzheimer’s disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES)
|
Wied, C. C. Gispen-De |
|
2009 |
13 |
4 |
p. 376-387 |
artikel |
22 |
Unawareness of weight and height - the effect on self-reported prevalence of overweight in a population-based study
|
Ramos, E. |
|
2009 |
13 |
4 |
p. 310-314 |
artikel |
23 |
Use of biomarkers in Alzheimer’s trials
|
Vellas, B. |
|
2009 |
13 |
4 |
p. 331 |
artikel |
24 |
Use of biomarkers to select the target population for clinical trials in subjects with mild cognitive impairment
|
Visser, P. J. |
|
2009 |
13 |
4 |
p. 344-345 |
artikel |
25 |
Use of CSF biomarkers in Alzheimer’s disease clinical trials
|
Blennow, K. |
|
2009 |
13 |
4 |
p. 358-361 |
artikel |
26 |
What we have learned from the myriad trials
|
Hendrix, S. B. |
|
2009 |
13 |
4 |
p. 362-364 |
artikel |
27 |
What we have learned from the xaliproden Sanofi-aventis trials
|
Douillet, P. |
|
2009 |
13 |
4 |
p. 365-366 |
artikel |